Fusion Pharma climbs as analysts flag radiopharmaceutical company as potential merger target

Targeted-oncology specialist draws upgrade at Raymond James after big premium paid is for Rayze Bio.

Previous post A record share of S&P 500 stocks have underperformed the index in 2023 as ‘weirdest bull market in decades’ marches on
Next post The 10 days that moved the stock market the most in 2023